Poland· PL-100516811
KORJUNY
A catumaxomab product containing catumaxomabum, registered in Poland by Lindis Biotech GmbH. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Catumaxomab is registered in 9 of 19 countries.
Countries holding a registration under ATC L01FX03 (catumaxomab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Catumaxomab · ATC L01FX03
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Catumaxomabum
- Manufacturer
- Lindis Biotech GmbH
- Country
- Poland (PL)
- ATC code
- L01FX03
- ATC class
- Catumaxomab
- Defined daily dose
- 21 mcg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Catumaxomab in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumKorjuny 10 µgAtnahs Pharma Netherlands
- CzechiaKORJUNYAtnahs Pharma Netherlands B.V., Amsterdam
- FinlandRemovabNeovii Biotech GmbH
- SwedenKorjuny 10 mikrogram Koncentrat till infusionsvätska, lösningAtnahs Pharma Netherlands B.V.
- SpainKORJUNY 10 MICROGRAMOS CONCENTRADO PARA SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- IrelandKorjuny 10 micrograms concentrate for solution for infusionAtnahs Pharma Netherlands B.V.
- IcelandKorjunyAtnahs Pharma Netherlands B.V.
- NetherlandsKorjuny 10 microgram concentraat voor oplossing voor infusieAtnahs Pharma Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Korjuny
- Liechtenstein · Korjuny
- Norway · Korjuny
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/98e8312f-d86f-4da7-9ebb-fba6f5b9a3a4 GET /v1/drugs/98e8312f-d86f-4da7-9ebb-fba6f5b9a3a4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "10 mcg",
"packaging": "Rpz ¦ EU/1/24/1826/001 ¦ 161471\n3 amp.-strzyk. 0,1 ml + 5 kaniuli",
"substance": "Catumaxomabum 10 mcg",
"common_name": "Catumaxomabum",
"pl_product_id": "100516811",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about catumaxomab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.